BECONASE

This brand name is authorized in United States. It is also authorized in France, Hong Kong SAR China, Ireland, Lithuania, Mexico, New Zealand, Tunisia, UK.

Active ingredients

The drug BECONASE contains one active pharmaceutical ingredient (API):

1	Beclometasone dipropionate UNII 4H7L9AI22I - BECLOMETHASONE DIPROPIONATE MONOHYDRATE
	Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity.
	Read more about Beclometasone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BECONASE Aqueous suspension for intranasal inhalation	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R01AD01	Beclometasone	R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	63295400
GB	Medicines & Healthcare Products Regulatory Agency	198725, 29405, 29454, 299795, 64981
HK	Department of Health Drug Office	28384
LT	Valstybinė vaistų kontrolės tarnyba	1011964
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	079M90
NZ	Medicines and Medical Devices Safety Authority	2138
TN	Direction de la Pharmacie et du Médicament	2113081
US	FDA, National Drug Code	0173-0388